Surveillance for Haemophilus influenzae meningitis cases was performed in Salvador, Brazil, before and after introduction of H. influenzae type b (Hib) immunization. The incidence of Hib meningitis decreased 69% during the 1-year period after initiation of Hib immunization (from 2.62 to 0.81 cases/100,000 person-years;
(Hib) polysaccharide conjugate vaccines. Hib is an important cause of meningitis, pneumonia, and epiglottitis in the pediatric population and is responsible each year for 12 million cases of invasive disease and 300,000 deaths worldwide among children aged !5 years [1] . Hib infection rates have been reduced dramatically in countries that have implemented Hib conjugate vaccine programs as part of routine infant immunization [1, 2] : in the United States, annual cases of Hib meningitis among children aged !5 years decreased from 110,000 cases to !200 cases within a 10-year period after licensure of Hib conjugate vaccines [3] .
In addition to preventing Hib invasive disease, several studies have shown that conjugate vaccines are effective in reducing nasopharyngeal colonization [4] [5] [6] [7] and therefore may confer protection to populations not targeted for immunization through herd immunity [8] . On the other hand, reduction of Hib carriage may open ecological niches for H. influenzae non-type b strains and therefore potentially increase the risk of colonization and invasive disease by these strains [9, 10] . H. influenzae non-type b strains are generally believed to be less pathogenic than Hib [11] and are an infrequent cause of severe invasive disease [12] [13] [14] . However, reports have shown that these strains can cause outbreaks of meningitis and bacteremia [11, 15] . Furthermore, in the conjugate vaccine era, the incidence of H. influenzae non-type b invasive disease has increased in certain geographical locations [16] [17] [18] . In Salvador, Brazil, through active surveillance for meningitis, we had the opportunity to examine the incidence of H. influenzae non-type b disease before and after introduction of routine Hib immunization. In the present study, we provide evidence for serotype replacement with H. influenzae type a associated with the use of the Hib conjugate vaccine.
METHODS

Study site.
The metropolitan region of Salvador is comprised of 30 municipalities in Northeast Brazil, with a total population of 3,208,893 inhabitants [19] . State health secretary protocol requires that suspected cases of meningitis from metropolitan Salvador be referred to the state infectious disease hospital for diagnosis and assessment of the need for isolation procedures. Notification of a case of meningitis to state health officials is mandatory, and this hospital reports 98% of the cases among residents of metropolitan Salvador [20] .
In August 1999, the Hib conjugate vaccine was introduced as part of the routine infant immunization program in Brazil. ord. Immunization cards were reviewed to obtain information on the timing and number of Hib conjugate vaccine doses administered before hospitalization.
Laboratory investigation. H. influenzae was identified according to Gram-stain morphology and growth requirement for factors V and X. Biotyping was performed by use of the indole spot (Difco Laboratories) and ornithine decarboxylase and urease (BBL Microbiology Systems) tests. Commercial antiserum (Difco Laboratories) was used to determine capsular serotype. Each isolate was tested for slide agglutination with the complete panel of type a-to type f-specific antisera and a saline control. Isolates were serotyped at 2 laboratories in Brazil, and those identified as a H. influenzae non-type b serotype and those with discordant results were reanalyzed at the Centers for Disease Control and Prevention (CDC). A seminested polymerase chain reaction (PCR) method was used to amplify serotype-specific and nonspecific DNA sequences from the H. influenzae capsular loci [22] . Isolates were defined as noncapsulated if agglutination was not observed with the 6 type-specific antisera and if PCR capsular loci sequences conserved among serotypes were not detectable by PCR [22] .
Pulsed-field gel electrophoresis (PFGE) was performed with SmaI-digested DNA [23, 24] of H. influenzae type a strains from Salvador and with those obtained during reference laboratory-based surveillance in Brazil and the United States. PFGE typing patterns were defined according to the criteria of Tenover et al. [25] . Closely related (1-3-band difference) and identical patterns were assigned a unique letter and number code, respectively.
Statistical analysis. Data entry and statistical analyses were performed with Epi Info version 6.04 software (CDC). Fisher's exact test or the x 2 test was used to compare proportions, and the Kruskal-Wallis test was used to compare continuous data. Cumulative incidence was calculated on the basis of the number of case patients from metropolitan Salvador and population counts from the 1996 national census. The pre-and postvaccine periods were defined as the 3.5-year interval before and 1-year interval after 9 September 1999, respectively. Rates from the prevaccine period were used as the expected value to calculate the probability, according to the Poisson distribution, of observing postvaccine period rates.
RESULTS
Active surveillance identified 522 case patients with H. influenzae meningitis during the 4.5-year period between 9 March 1996 and 8 September 2000 (figures 1 and 2). In 483 (93%) of these case patients, isolates were serotyped by slide agglutination; 467 (96.7%) of the 483 isolates were Hib, 13 (2.7%) were H. influenzae type a, 2 (0.4%) were noncapsulated, and 1 (0.2%) was H. influenzae type f. PCR-based detection of capsular loci sequences confirmed the serotype of all H. influenzae non-type b isolates (results not shown). Isolates were serotyped from 431 (92%) of 467 cases identified during the prevaccine period and 52 (95%) of 55 of the cases identified during the postvaccine period. The proportion of H. influenzae type a cases increased from 5 (1.2%) of 431 to 8 (15.4%) of 52 ( ) after introduction of routine Hib immunization, P ! .001 but no significant increase was observed in the proportion of cases due to other H. influenzae non-type b isolates.
The incidence of H. influenzae meningitis among the 357 (68%) of the 522 patients who resided within metropolitan Salvador, decreased 64% during the 1-year period after the introduction of Hib immunization (pre-and postvaccine rates: 2.88 and 1.03 cases/100,000 person-years, respectively; P ! ; table 1). This decrease was a result of the significant re-.001 duction in the incidence of Hib meningitis among children aged !2 years (77%) and those aged 2-4 years (49%). However, the incidence of H. influenzae type a meningitis increased 8-fold after introduction of routine Hib immunization (pre-and postvaccine rates; 0.02 and 0.16 cases/100,000 person-years, respectively;
). There was a significant difference be-P p .008 tween the rates of H. influenzae type a meningitis between preand postvaccine periods in the target population for Hib immunization (children aged !2 years; 0 and 1.77 cases/100,000 person-years, respectively; ), but not in the other age P p .049 groups (table 1) .
H. influenzae type a meningitis cases did not cluster spatially with respect to the neighborhood of residence during pre-and postvaccine periods. There were no significant differences with respect to age, sex, prior hospitalization, attendance at day care centers, and underlying chronic diseases between H. influenzae type a and H. influenzae non-type a meningitis cases ( Information on Hib immunization status was obtained from 14 (52%) of 27 H. influenzae meningitis case patients who were identified in the postvaccine period and were in the vaccine target population. Of the 4 case patients with H. influenzae type a meningitis interviewed, 2 had completed a 3-dose Hib immunization schedule, and 2 had received 2 doses of the vaccine (table 3) . In contrast, of the 10 interviewed case patients with Hib meningitis, 4 had not received any doses of the conjugate vaccine, and 6 had received 1 dose before acquiring their illness.
The clinical manifestations seen in the 13 H. influenzae type a meningitis cases were similar in severity to those seen in the 549 H. influenzae non-type a cases (547 with Hib strains and 2 with noncapsulated strains) for whom clinical information and isolate serotype were obtained (table 2). Significant differences were not observed in mortality from meningitis due to H. influenzae type a and H. influenzae non-type a strains (casefatality ratios, 23% vs. 16%, respectively; ) or disease P 1 .05 caused by these strains during the periods before or after the initiation of the Hib immunization campaign (results not shown). Neurological sequelae, such as hydrocephalus and auditory deficits, were observed at similar frequencies among survivors with H. influenzae type a (20%) and H. influenzae non- 
DISCUSSION
The present study's findings demonstrate the major public health impact of Hib immunization 1 year after its introduction in Brazil. The benefits are similar to those observed previously in countries, mostly in the developed world, that have adopted Hib conjugate vaccines [1] . Within the first year of the campaign in Salvador, overall Hib meningitis rates decreased 77% among children aged !2 years. Serious neurological sequelae were identified during hospitalization in 120% of children with H. influenzae meningitis. In addition to decreased meningitis and mortality rates, a major impact of Hib immunization in Salvador was the prevention of long-term morbidity and social burdens due to neurological sequelae.
In parallel, surveillance in Salvador identified a small but significant increase in H. influenzae type a meningitis rates. H. influenzae non-type b has been described to be the cause of invasive disease [11, 14-18, 26, 27] . However, strong evidence of serotype replacement has not been detected anywhere since Hib conjugate vaccines were introduced in the late 1980s [10] . In the present study, the evidence that serotype replacement occurred after introduction of routine Hib immunization in Salvador, Brazil is as follows: (1) a significant increase in the incidence of H. influenzae type a meningitis cases was observed after the initiation of the Hib conjugate vaccine campaign; (2) all H. influenzae type a strains belonged to 2 clonal groups present in Salvador before the introduction of the Hib conjugate vaccine; and (3) H. influenzae type a meningitis was documented in subjects who had previously been immunized with the conjugate vaccine. Because surveillance was limited to those with meningitis, the study's findings may not apply to the other forms of invasive H. influenzae disease. Improved surveillance is an alternative explanation for the serotype shift identified after the introduction of the vaccine. However, increases in the rate of disease due to non-Hib other than H. influenzae type a were not observed. Moreover, differential case ascertainment for H. influenzae type a and nontype a meningitis cases is unlikely, given the similarity between patient groups and clinical presentations (table 2). Outbreaks of H. influenzae type a disease have been reported [11, 15] , but H. influenzae type a cases identified in this study were not clustered in space or time and did not occur in specific risk groups, other than the pediatric population targeted by the immunization campaign. In addition, the similarity of host characteristics between H. influenzae type a and H. influenzae non-type a cases indicates that the increase in H. influenzae type a disease was not associated with a change in the population at risk for H. influenzae meningitis. Introduction of a new hypervirulent strain was not observed, because H. influenzae type a isolates from the postvaccine period had PFGE patterns identical to those of isolates from the prevaccine period.
Serotype replacement has not been previously detected for H. influenzae nasopharyngeal carriage [4, 6, 7] or invasive disease [12, 28] in the postvaccine era. Few reports have described increased rates of H. influenzae non-type b invasive disease in regions where Hib conjugate vaccines have been used [16] [17] [18] , but molecular typing studies were not performed to determine whether increased rates were due to serotype replacement. Furthermore, long-term surveillance in countries such as the United States, which have used conjugate vaccines for 110 years, has not found sustained increases in the rates of H. influenzae non-type b invasive disease [29] . We demonstrated that 2 clonally related groups of strains were responsible for transmission of H. influenzae type a meningitis in Salvador. Identification of serotype replacement in meningitis cases, therefore, appears to be due in part to the presence of circulating virulent H. influenzae type a clones not found in other locations. The presence or lack of circulating virulent H. influenzae non-type b clones may be an explanation why increased rates of H. influenzae non-type b disease after Hib immunization have been observed in few epidemiological settings. However, we found that H. influenzae type a strains from geographically disparate regions of Brazil had PFGE patterns identical to those in Salvador, which indicates that dissemination of these clonal groups is not a local phenomenon that is restricted to our surveillance region. With increasing reports (table 2) . Increased virulence among H. influenzae type a, which was generally considered to be a rare cause of invasive disease in the prevaccine era [11, 15, 31] , appears to be associated with partial deletion of 1 of 2 bexA copies within duplicated cap loci [15] and/or amplification of cap loci [30] . Virulent H. influenzae type a strains identified in this study were responsible for sporadic meningitis cases in the prevaccine period. Introduction of the Hib immunization contributed to an increase in the rates of meningitis due to these strains. Our study found that cases of H. influenzae type a meningitis occurred among infants who previously had received у2 vaccine doses. We propose that, in Salvador, the use of Hib conjugate vaccines provided circulating virulent type a strains an increased opportunity to replace Hib during nasopharyngeal colonization.
Although surveillance in Salvador identified a significant increase in the rate of H. influenzae type a meningitis that resulted from serotype replacement, the impact of this finding is small in comparison to substantial and large reduction in the burden of Hib meningitis attributable to the use of the conjugate vaccine (table 1) . Without question, the public health priority for H. influenzae disease is the widespread introduction of the Hib conjugate vaccine in developing countries, where the cost of conjugate vaccines has thus far precluded their use. More than 10 years after the introduction of Hib conjugate vaccines, immunization schedules contributed to !2% reduction in the global burden of Hib disease [1] . This situation is expected to improve as efforts progress to reduce vaccine costs, as was done recently in Brazil [32] , and as more developing countries, such as those in Latin America, adopt Hib immunization programs. However, the finding of this study suggests that, as global immunization coverage expands, continued surveillance for H. influenzae will be needed to monitor potential increases in disease due to serotype replacement.
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